GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
Read More
Further results from the UK Salford Lung Study have been unveiled showing that GlaxoSmithKline’s Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic obstructive pulmonary disease.
Read More
A “ground-breaking” UK study has shown that GlaxoSmithKline’s Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Read More
